What’s next for mRNA after COVID-19? Well, the future looks bright ― just ask the team at NorthX Biologics.
In the forests of Matfors, Sweden, NorthX Biologics is implementing a small to mid-range manufacturing process to support mRNA applications extending beyond infectious disease management to gene therapy, gene replacement, and monoclonal antibodies.
What motivated this ambitious endeavor? In short, a passionate community looking to make a difference. For Ola Tuvesson, Chief Technical Officer, the word “purpose” comes to mind. Agnes Zimmer, Head of Process Development, finds boldness in trying new things.
In this episode, we follow how the team’s initial conversations started a two-year process that led to collaboration with Cytiva and academic partners and the opening of their new facility ― a space for early-stage scientists to run tests on their way to clinical trials; a space to identify and solve challenges; a space for discovery.
So, where will the mRNA journey go next?
For more stories from Cytiva, visit
https://www.cytiva.com/behind-biopharmaFor more information on mRNA, visit
https://www.cytiva.com/mrnaEpisode features: Ola Tuvesson, Agnes Zimmer, Klara Yngvesson.
